Editors: Kelly Maurelus, MD FAAEM and Michael C. Bond, MD FAAEM
Originally Published: Common Sense January/February 2017
ED physicians frequently treat and admit patients for infectious diseases. Judicious use of antimicrobial therapy is important in order to avoiding the development of antimicrobial resistance and adverse drug effects. Procalcitonin (PCT) is one of several bbiomarkers which may be useful in decreasing unnecessary antibiotic therapy. Specifically, PCT levels should be low for viral, as opposed to bacterial, infections. Procalcitonin has been studied as both a diagnostic and prognostic marker in various types of systemic and organ-specific infections. The potential for PCT to reduce unnecessary antimicrobial therapy has been shown in several observational and randomized controlled trials performed in outpatient, inpatient, and ICU environments. The most robust evidence is in sepsis and pulmonary infections. Here we review some of the evidence behind the use of PCT in acute infectious disease management.
